(Reuters) -Italian medical diagnostics group DiaSorin on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year. The group’s 2024 revenue increased 3% year-on-year at constant exchange rates to 1.18 billion euros ($1.28 billion), while revenue was up 7% when excluding […]
Health
Italy’s DiaSorin ex-Covid revenue in line with guidance
Audio By Carbonatix
(Reuters) -Italian medical diagnostics group DiaSorin on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year.
The group’s 2024 revenue increased 3% year-on-year at constant exchange rates to 1.18 billion euros ($1.28 billion), while revenue was up 7% when excluding its COVID-related business, in line with guidance.
The group proposed a dividend of 1.20 euro per share.
Shares were 2.6% lower after the results.
(Reporting by Michela Stasio; Editing by Kirsten Donovan)